BNET Industries
Last Fiscal Year Sales:$7.5M
- Private
- US
Dow Jones Description
Protein Sciences Corporation (PSC) is a privately held vaccine company located in Meriden, CT. PSC is dedicated to the development and commercialization of vaccines and biopharmaceuticals using its patented BEVS manufacturing platform. In addition to developing its own pipeline of proprietary vaccine candidates, PSC operates two additional business units; a product development and contract manufacturing service business (GeneXpress ) whereby clients can access and leverage PSC's manufacturing technology and regulatory experience as well as line of Research Products for the scientific community.
Number of Employees 34
Peer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
Recent Events
-
Emergent BioSolutions continues fight over failed merger
-
Contract award may end dispute with EBS
-
Emergent gets boost from FDA
-
Rockville-based Emergent gets boost from regulator
News & Analysis
Filter by
protein sciences corp. - All News and Analysis
Applied Protein Sciences and Biomodels Collaborate to Boost Supportive Cancer Care
- 2009-04-28
MOUNTAIN VIEW, Calif. -- Applied Protein Sciences, a biotechnology start-up focused on preventing mucositis, announced today that it has entered into a strategic alliance with Biomodels. This alliance allows...
Emergent BioSolutions Ends Efforts to Acquire Protein Sciences
- 2009-01-07
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has ended all activities related to its planned acquisition of Protein Sciences Corporation PSC. Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions, stated, "After protracted efforts to determine whether a mutually agreeable acquisition could be...
Statement by Emergent BioSolutions in Response to Attempt by Protein Sciences Corporation to Terminate Asset Purchase Transaction
- 2008-07-29
ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) issued the following statement in response to the announcement by Protein Sciences Corporation PSC that PSC is attempting to terminate its asset purchase agreement between the two companies: "The asset purchase agreement between Emergent BioSolutions and PSC has not been terminated. PSC's...
Emergent BioSolutions Initiates Lawsuit Against Protein Sciences and Its Senior Management Regarding Delayed Asset Acquisition
- 2008-07-09
* Suit alleges fraud by PSC management and contract breaches by PSC * Emergent seeks immediate repayment of $10 million bridge loan secured by all of PSC's assets plus other relief ROCKVILLE, Md. -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has initiated a lawsuit against Protein...
Rockville-based Emergent BioSolutions buys Protein Sciences
- 2008-05-28
Emergent BioSolutions is purchasing Protein Sciences Corp., which makes the next-generation flu vaccine the government has put on the fast-track approval process, The Washington Post reported. Rockville- based Emergent could pay more than $75 million for Protein Sciences, based in Meriden, Conn., the newspaper said in its Tuesday editions. According...
Emergent BioSolutions to Acquire Protein Sciences' Phase III Recombinant Flu Vaccine Candidate, FluBlok®, and Related Novel Platform Technology
- 2008-05-27
* FluBlok BLA granted fast track status and priority review by FDA; would be the first licensed recombinant hemagglutinin cell culture influenza vaccine
Diamyd Medical AB increases stake in US biotech company Protein Sciences Corporation
- 2007-11-08
NORDIC BUSINESS REPORT-8 November 2007-Diamyd Medical AB increases stake in US biotech company Protein Sciences CorporationC1994-2007 M2 COMMUNICATIONS LTD http://www.m2.com Swedish life science company Diamyd Medical AB announced on Thursday (8 November) that it has increased its holding in the US biotech company Protein Sciences Corporation. Diamyd Medical...
ViRexx Announces Manufacturing and Supply Agreement with Protein Sciences Corporation for Hepavaxx B Vaccine
- 2005-04-28
EDMONTON, Alberta -- ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy treatments for tumors today announced the completion of a Collaborative Development Agreement with Protein Sciences Corporation PSC, a biopharmaceutical service company, for the ...
ViRexx Announces Manufacturing and Supply Agreement with Protein Sciences Corporation for Hepavaxx B Vaccine.
- 2005-04-28
EDMONTON, ALBERTA, Apr 28, 2005 CCNMatthews via COMTEX ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy treatments for tumors today announced the completion of a Collaborative Development Agreement with Protein Sciences Corporation PSC,...
Protein Sciences to expand tests of new flu vaccine
- 2004-10-29
While the USA heads into flu season with a shortage of vaccine, a handful of companies are pushing ahead to develop a potentially faster way to make them. Thursday, Protein Sciences, a small, Connecticut-based biotech company, said it had received the Food and Drug Administration's approval to conduct advanced...
- 1
- 2
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
